Tags

Type your tag names separated by a space and hit enter

A comparative study of cisapride and ranitidine at controlling oesophageal acid exposure in erosive oesophagitis.
Aliment Pharmacol Ther 1995; 9(6):661-6AP

Abstract

BACKGROUND

The severity of gastro-oesophageal reflux disease is generally considered to be related to the extent of oesophageal acid exposure. Current therapies include antisecretory and prokinetic agents. We compared two of these, ranitidine and cisapride, in their ability to lower oesophageal acid exposure in patients with erosive oesophagitis.

METHODS

Seven patients with Savary-Miller's grade II-IV oesophagitis and with oesophageal contact time > or = 8% were studied. Mean lower oesophageal sphincter pressure was 4.6 mmHg. Oesophageal acid contact time was 25.6 +/- 5.6%. Each patient received ranitidine 150 mg b.d., ranitidine 150 mg q.d.s., or cisapride 10 mg q.d.s. in a randomized 3-way cross-over design. Intra-oesophageal pH was monitored during 24 h for each of these treatments in a controlled hospital environment, while consuming a high fat, high calorie diet.

RESULTS

Cisapride and ranitidine at both doses decreased the acid contact time and the number of reflux episodes. However, a minority of patients treated with ranitidine, and none with cisapride, diminished their oesophageal acid contact time to a normal value of < 5%. No treatment significantly decreased nocturnal acid exposure.

CONCLUSION

In patients with severe gastro-oesophageal reflux disease both cisapride and ranitidine demonstrably lower oesophageal acid exposure, but neither therapy predictably normalizes it.

Authors+Show Affiliations

Department of Medicine, Northwestern University Medical School, Chicago, Illinois 60611, USA.No affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8824654

Citation

Pouderoux, P, and P J. Kahrilas. "A Comparative Study of Cisapride and Ranitidine at Controlling Oesophageal Acid Exposure in Erosive Oesophagitis." Alimentary Pharmacology & Therapeutics, vol. 9, no. 6, 1995, pp. 661-6.
Pouderoux P, Kahrilas PJ. A comparative study of cisapride and ranitidine at controlling oesophageal acid exposure in erosive oesophagitis. Aliment Pharmacol Ther. 1995;9(6):661-6.
Pouderoux, P., & Kahrilas, P. J. (1995). A comparative study of cisapride and ranitidine at controlling oesophageal acid exposure in erosive oesophagitis. Alimentary Pharmacology & Therapeutics, 9(6), pp. 661-6.
Pouderoux P, Kahrilas PJ. A Comparative Study of Cisapride and Ranitidine at Controlling Oesophageal Acid Exposure in Erosive Oesophagitis. Aliment Pharmacol Ther. 1995;9(6):661-6. PubMed PMID: 8824654.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A comparative study of cisapride and ranitidine at controlling oesophageal acid exposure in erosive oesophagitis. AU - Pouderoux,P, AU - Kahrilas,P J, PY - 1995/12/1/pubmed PY - 1995/12/1/medline PY - 1995/12/1/entrez SP - 661 EP - 6 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 9 IS - 6 N2 - BACKGROUND: The severity of gastro-oesophageal reflux disease is generally considered to be related to the extent of oesophageal acid exposure. Current therapies include antisecretory and prokinetic agents. We compared two of these, ranitidine and cisapride, in their ability to lower oesophageal acid exposure in patients with erosive oesophagitis. METHODS: Seven patients with Savary-Miller's grade II-IV oesophagitis and with oesophageal contact time > or = 8% were studied. Mean lower oesophageal sphincter pressure was 4.6 mmHg. Oesophageal acid contact time was 25.6 +/- 5.6%. Each patient received ranitidine 150 mg b.d., ranitidine 150 mg q.d.s., or cisapride 10 mg q.d.s. in a randomized 3-way cross-over design. Intra-oesophageal pH was monitored during 24 h for each of these treatments in a controlled hospital environment, while consuming a high fat, high calorie diet. RESULTS: Cisapride and ranitidine at both doses decreased the acid contact time and the number of reflux episodes. However, a minority of patients treated with ranitidine, and none with cisapride, diminished their oesophageal acid contact time to a normal value of < 5%. No treatment significantly decreased nocturnal acid exposure. CONCLUSION: In patients with severe gastro-oesophageal reflux disease both cisapride and ranitidine demonstrably lower oesophageal acid exposure, but neither therapy predictably normalizes it. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/8824654/A_comparative_study_of_cisapride_and_ranitidine_at_controlling_oesophageal_acid_exposure_in_erosive_oesophagitis_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&amp;sid=nlm:pubmed&amp;issn=0269-2813&amp;date=1995&amp;volume=9&amp;issue=6&amp;spage=661 DB - PRIME DP - Unbound Medicine ER -